Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
2007
Safinamide potentiates the effects of DA-agonist in early stage PD patients
Anand R, Onofrj M, Shapira A, Rossetti S, on behalf of the Study 015 Investigators.
11th International Congress of the Movement Disorder Society June 3-7, 2007 - Instanbul, Turkey
Overlap of congnitive deficits in PD and AD diseases:potential for use of safinamide
Sharma T, Anand R and Hartman R.
11th International Congress of the Movement Disorder Society June 3-7, 2007 - Instanbul, Turkey
Cognitive effects of safinamide in early PD patients
Sharma T, Anand R, Stocchi F, Borgohain R and Rossetti S.
11th International Congress of the Movement Disorder Society June 3-7, 2007 - Instanbul, Turkey
Safinamide, a new generation, anti-Parkinson agent is Effective and well-tolerated in early PD patients on a stable dose of a single DA-Agonist:results of a randomized,international, placebo-controlled,add-on,Phase III trial (Study 015)
Stocchi F, Borgohain R, Onofrj M, Shapira A, Bhatt M, Lorenzana P, Rossetti S, Anand R on behalf of the Study 015 Investigators.
59th meeting of the AAN - April 28 – May 5 2007 - Boston,US
Neurotherapeutics, Volume 4, Issue 1, January 2007, Pages 110-116